<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT943-10502</title>
	</head>
	<body>
		<main>
			<p>940804 FT  04 AUG 94 / International Company News: RPR seeking approval for anti-cancer drug Rhone-Poulenc Rorer, the US pharmaceuticals arm of Rhone-Poulenc of France, yesterday announced it had submitted licence applications in the US, Canada and Europe, for Taxotere, its anti-cancer drug. The submissions represent the first global application since RPR was acquired by Rhone-Poulenc in 1990. The submissions are for use in breast cancer and lung cancer.</p>
		</main>
</body></html>
            